Myriad Genetics Inc (MYGN): Price-to-Revenue Coefficient

Myriad Genetics, Inc. (MYGN) is expanding its leadership in molecular testing, pursuing net profit through automation. The current price-to-sales ratio confirms this trend, with the metric reaching 0.70. Success relies on physician recognition of its technologies and insurance reimbursements. Simultaneously, Myriad Genetics, Inc. (MYGN) is implementing digital document management and strictly controlling the disposal of hazardous biomaterials within its laboratories.

Myriad Genetics (MYGN): Price-to-Revenue Ratio from 07/04/2022 to 11/13/2026

Myriad Genetics Corp (MYGN) - metric breakdowns and financial figures

- current quotes and average value forecast:

Market Price myriad.com|MYGN - Price Target Chart

- stock exchange capitalization data:

Market Capitalization Myriad Genetics Corp|MYGN - Enterprise Value

- company book value details:

Net Assets per Share Myriad Genetics|MYGN - Company Book Value|Market Capitalization to Book Value myriad.com|MYGN - Aggregate Company Assets

- debt obligations and liquidity statistics:

- net income and valuation ratios data:

MYGN - Net Profit|Net Profit Forecast Myriad Genetics, Inc.|MYGN - Price to Earnings Ratio|Future Price to Earnings Multiple Myriad Genetics Inc|MYGN - PEG Multiple|Enterprise Value to EBITDA Multiple Myriad Genetics Corp|MYGN - Operating profit EBITDA|Net earnings per one share for the last twelve months Myriad Genetics|MYGN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months myriad.com|MYGN - Earnings growth in current year|Expected net earnings per share growth next year Myriad Genetics, Inc.

- total revenue and sales volume data:

MYGN - Company Sales|Company Projected Revenue Volume myriad.com|MYGN - P/S Multiple|Market Cap to Expected Sales Ratio Myriad Genetics Corp

Fundamental company analysis:myriad.com, MYGN

Myriad Genetics, Inc. (MYGN) operates under intense pricing pressure and a struggle for insurance reimbursements within the mass genetic testing sector. By analyzing the P/S trajectory, an investor assesses the company's market value relative to its revenue, which allows for the separation of actual sales efficiency from speculative expectations and determines whether the market is overpaying for the business during a period of declining margins.

Competing companies